Use of metformin in diseases of aging

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Metformin is the most commonly prescribed medication for type 2 diabetes (T2DM) in the world. It has primacy in the treatment of this disease because of its safety record and also because of evidence for reduction in the risk of cardiovascular events. Evidence has accumulated indicating that metformin is safe in people with stage 3 chronic kidney disease (CKD-3). It is estimated that roughly one-quarter of people with CKD-3 and T2DM in the United States (well over 1 million) are ineligible for metformin treatment because of elevated serum creatinine levels. This could be overcome if a scheme, perhaps based on pharmacokinetic studies, could be developed to prescribe reduced doses of metformin in these individuals. There is also substantial evidence from epidemiologic studies to indicate that metformin may not only be safe, but may actually benefit people with heart failure (HF). Prospective, randomized trials of the use of metformin in HF are needed to investigate this possibility.

Original languageEnglish (US)
Article number490
JournalCurrent Diabetes Reports
Volume14
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Metformin
Heart Failure
Risk Reduction Behavior
Chronic Renal Insufficiency
Type 2 Diabetes Mellitus
Epidemiologic Studies
Creatinine
Pharmacokinetics
Safety
Serum

Keywords

  • Aging
  • Chronic kidney disease
  • Diseases
  • Heart failure
  • Lactic acidosis
  • Metformin
  • Pharmacotherapy
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Medicine(all)

Cite this

Use of metformin in diseases of aging. / Miles, John M.; Rule, Andrew D; Borlaug, Barry A.

In: Current Diabetes Reports, Vol. 14, No. 6, 490, 2014.

Research output: Contribution to journalArticle

@article{6743c1b706e84db8a1b484205a13dd70,
title = "Use of metformin in diseases of aging",
abstract = "Metformin is the most commonly prescribed medication for type 2 diabetes (T2DM) in the world. It has primacy in the treatment of this disease because of its safety record and also because of evidence for reduction in the risk of cardiovascular events. Evidence has accumulated indicating that metformin is safe in people with stage 3 chronic kidney disease (CKD-3). It is estimated that roughly one-quarter of people with CKD-3 and T2DM in the United States (well over 1 million) are ineligible for metformin treatment because of elevated serum creatinine levels. This could be overcome if a scheme, perhaps based on pharmacokinetic studies, could be developed to prescribe reduced doses of metformin in these individuals. There is also substantial evidence from epidemiologic studies to indicate that metformin may not only be safe, but may actually benefit people with heart failure (HF). Prospective, randomized trials of the use of metformin in HF are needed to investigate this possibility.",
keywords = "Aging, Chronic kidney disease, Diseases, Heart failure, Lactic acidosis, Metformin, Pharmacotherapy, Type 2 diabetes",
author = "Miles, {John M.} and Rule, {Andrew D} and Borlaug, {Barry A}",
year = "2014",
doi = "10.1007/s11892-014-0490-4",
language = "English (US)",
volume = "14",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "6",

}

TY - JOUR

T1 - Use of metformin in diseases of aging

AU - Miles, John M.

AU - Rule, Andrew D

AU - Borlaug, Barry A

PY - 2014

Y1 - 2014

N2 - Metformin is the most commonly prescribed medication for type 2 diabetes (T2DM) in the world. It has primacy in the treatment of this disease because of its safety record and also because of evidence for reduction in the risk of cardiovascular events. Evidence has accumulated indicating that metformin is safe in people with stage 3 chronic kidney disease (CKD-3). It is estimated that roughly one-quarter of people with CKD-3 and T2DM in the United States (well over 1 million) are ineligible for metformin treatment because of elevated serum creatinine levels. This could be overcome if a scheme, perhaps based on pharmacokinetic studies, could be developed to prescribe reduced doses of metformin in these individuals. There is also substantial evidence from epidemiologic studies to indicate that metformin may not only be safe, but may actually benefit people with heart failure (HF). Prospective, randomized trials of the use of metformin in HF are needed to investigate this possibility.

AB - Metformin is the most commonly prescribed medication for type 2 diabetes (T2DM) in the world. It has primacy in the treatment of this disease because of its safety record and also because of evidence for reduction in the risk of cardiovascular events. Evidence has accumulated indicating that metformin is safe in people with stage 3 chronic kidney disease (CKD-3). It is estimated that roughly one-quarter of people with CKD-3 and T2DM in the United States (well over 1 million) are ineligible for metformin treatment because of elevated serum creatinine levels. This could be overcome if a scheme, perhaps based on pharmacokinetic studies, could be developed to prescribe reduced doses of metformin in these individuals. There is also substantial evidence from epidemiologic studies to indicate that metformin may not only be safe, but may actually benefit people with heart failure (HF). Prospective, randomized trials of the use of metformin in HF are needed to investigate this possibility.

KW - Aging

KW - Chronic kidney disease

KW - Diseases

KW - Heart failure

KW - Lactic acidosis

KW - Metformin

KW - Pharmacotherapy

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84901583038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901583038&partnerID=8YFLogxK

U2 - 10.1007/s11892-014-0490-4

DO - 10.1007/s11892-014-0490-4

M3 - Article

VL - 14

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 6

M1 - 490

ER -